Previous Close | 0.3000 |
Open | 0.3000 |
Bid | 0.0500 |
Ask | 4.8000 |
Strike | 90.00 |
Expire Date | 2024-06-21 |
Day's Range | 0.3000 - 0.3000 |
Contract Range | N/A |
Volume | |
Open Interest | 9 |
On May 30, 2024, Gail Marcus, Director at Natera Inc (NASDAQ:NTRA), executed a sale of 2,000 shares of the company at a price of $110.17 per share.
On May 28, 2024, Rowan Chapman, Director at Natera Inc (NASDAQ:NTRA), sold 4,856 shares of the company.
AUSTIN, Texas, May 30, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC) 2024 taking place June 1–5, 2024.